Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ:RXRX), a leading tech-bio company decoding biology through advanced data science and automation.

Recursion's end-to-end platform is designed to connect discovery through development by integrating proprietary multimodal datasets, purpose-built AI models, and experimental biology. The addition of Citeline's real-world data and evidence capabilities strengthens this foundation, enabling more precise trial design, improved site selection, and faster, more informed development decisions.